Narrative review outlines miRNA-based strategies and challenges in pancreatic ductal adenocarcinoma management.
Tiny RNA tricks could help immunotherapy fight pancreatic cancer
This narrative review examines miRNA-based strategies within the context of pancreatic ductal adenocarcinoma treatment options available tod…
MicroRNAs may help immunotherapy work in hard-to-treat pancreatic cancer by reshaping the tumor environment.
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort
Most patients on strong pancreatic cancer chemo needed a dose change
This cohort study included 514 patients with pancreatic ductal adenocarcinoma treated at UCSF oncology clinics. XGBoost models showed AUCs r…
Over 60% of patients with pancreatic cancer needed a dose adjustment during treatment with FOLFIRINOX at UCSF clinics.
Systematic review and meta-analysis of CLDN18.2 expression prevalence in pancreatic ductal adenocarcinoma
Half of Pancreatic Cancers May Have a Hidden Target for New Therapies
This systematic review and meta-analysis evaluated CLDN18.2 expression prevalence in 2,025 adult patients with pancreatic ductal adenocarcin…
A hidden doorway may exist inside many pancreatic tumors.
Narrative review reports Onca model performance on pancreatic cancer tasks versus other LLMs
New AI tool helps doctors find pancreatic cancer trials faster
This narrative review and model development report evaluates an open 9B dense language model, Onca, against four comparators for pancreatic …
A new AI tool helps doctors quickly match patients with pancreatic cancer trials using open data.
Narrative review on fructose metabolism in pancreatic ductal adenocarcinoma stress tolerance
Fructose Fuels Pancreatic Cancer Survival
This narrative review synthesizes evidence on fructose metabolism in pancreatic ductal adenocarcinoma. It describes fructose uptake and synt…
Understanding how sugar and stress signals work together opens doors for new ways to starve these tumors.
PRISM EHR-based model identifies adults at high risk for pancreatic ductal adenocarcinoma in real-world setting.
Your Medical Records Might Flag Pancreatic Cancer Years Before Symptoms Appear
In a prospective multicenter cohort study of 6,282,123 adults, an EHR-based risk model identified individuals at high risk for pancreatic du…
An AI tool using routine health records can flag pancreatic cancer risk up to 3.5 years before symptoms appear in adults 40 and older.
Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
AI Now Reads Tumor Slides Like a Radiologist — and Shows Its Work
This review/commentary outlines a Virtual Spectral Decomposition (VSD) methodological framework for analyzing digital pathology and imaging …
A new AI system reads cancer slides like a doctor and explains exactly which biological features drove each diagnosis.
Gemcitabine exposure associated with higher TP53 and PI3K pathway alterations in pancreatic ductal adenocarcinoma tumors.
AI Finds Hidden Keys to Pancreatic Cancer Survival
This cohort study analyzed 184 pancreatic ductal adenocarcinoma tumors to assess the association between gemcitabine exposure and molecular …
Age and gemcitabine exposure drive distinct genetic patterns in pancreatic cancer, directly influencing survival rates for patients with key…
Review of Virtual Spectral Decomposition for pancreatic cancer detection on CT scans
Virtual spectral decomposition shows promise for detecting pancreatic cancer field effects on standard CT scans.
This review and synthesis evaluates a computational imaging method, Virtual Spectral Decomposition (VSD), applied to standard portal-venous …
A new image analysis method can spot subtle changes in the pancreas on standard CT scans, helping to find early signs of cancer before a tum…
Review of CAR-T cell therapy for pancreatic ductal adenocarcinoma reports no specific outcomes or safety data.
First CAR-T for Pancreatic Cancer Approved
This narrative review addresses the application of CAR-T cell therapy for pancreatic ductal adenocarcinoma. However, the source explicitly s…
For the first time, a new drug approved for pancreatic cancer uses immune cells to attack solid tumors instead of just blood cancers.
Tumor-associated neutrophils regulate PDAC progression via TGF-β and CXCR2 pathways
Can stopping white blood cells help stop pancreatic cancer from growing?
This systematic review examined tumor-associated neutrophils (TANs) in patients with pancreatic ductal adenocarcinoma (PDAC). The analysis d…
White blood cells that shield pancreatic cancer from treatment can be reprogrammed to fight the disease instead of fueling its growth.
Epigenomic ctDNA profiling identifies PDAC subtypes and improves prognostication over tissue-based methods in metastatic disease.
Can a blood test predict pancreatic cancer subtypes better than tissue samples?
This multi-institutional cohort study evaluated epigenomic profiling of circulating tumor DNA (ctDNA) for subtyping pancreatic ductal adenoc…
A new blood test matches tissue samples and predicts patient outcomes better for metastatic pancreatic cancer, offering a hopeful step towar…